Death receptor‐3 mediates apoptosis in human osteoblasts under narrowly regulated conditions
- 19 September 2006
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 209 (3) , 1021-1028
Abstract
We previously reported that a soluble form of the TNF‐family receptor death receptor‐3 (DR3) is expressed in osteoblasts. DR3 regulates death or differentiation in other tissues, and DR3 ligands occur in bone, but the function of DR3 in the osteoblast was unknown. We studied the expression of DR3 and the effects crosslinking antibodies to DR3 or of natural DR3 ligands in human osteoblasts. Western analysis showed that nontransformed osteoblasts and the MG63 osteosarcoma cell line produce both soluble decoy receptor and transmembrane isoforms of DR3. Cell surface labeling showed that low and high DR3‐expressing osteoblast populations occur. Verification of by cloning showed a point mutation in DR3 from MG63 cells. Activation of DR3 by antibody crosslinking or with DR3 ligands caused apoptosis in osteoblasts and in MG63 cells, but only in low‐density cell cultures. In dense cultures apoptosis did not occur, but nuclear factor‐κB nuclear translocation was observed under some conditions. Crosslinking of DR3 in high‐density MG63 cultures blocked expression of bone matrix elements. DR3 activation in high‐density nontransformed osteoblasts had only minor effects on cell maturation. We conclude that DR3 activation can mediate apoptosis in osteoblasts. Its activity is, however, highly restricted by its soluble ligand‐binding isoform and possibly also by alternate survival signals. In the presence of survival signals, DR3 may affect cell maturation although effects on differentiation were clearly seen only in the MG63 transformed cell line. J. Cell. Physiol. 209: 1021–1028, 2006.Keywords
This publication has 39 references indexed in Scilit:
- Comparative modeling of TNFRSF25 (DR3) predicts receptor destabilization by a mutation linked to rheumatoid arthritisBiochemical and Biophysical Research Communications, 2005
- Expression and function of TNF-family proteins and receptors in human osteoblasts☆Bone, 2003
- Heterogeneity among patients with tumor necrosis factor receptor–associated periodic syndrome phenotypesArthritis & Rheumatism, 2003
- A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotypeHuman Molecular Genetics, 2002
- MODULATION BY SOLUBLE FACTORS OF GELATINASE ACTIVITIES RELEASED BY OSTEOBLASTIC CELLSCytokine, 2000
- New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage studyProceedings of the National Academy of Sciences, 1998
- TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)Immunity, 1997
- Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95Science, 1996
- Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?Bone, 1994
- Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activationCell, 1993